Lijing Fang

Prof. Dr. Lijing Fang


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JZJiwei Zheng
Jiwei Zheng
WHWanyi He
Wanyi He
JLJing Li
Jing Li
XFXuejia Feng
Xuejia Feng
YLYanyan Li
Yanyan Li
LFLijing Fang
Lijing Fang

23 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJianchao Zhang
Jianchao Zhang
CCCongli Chen
Congli Chen
XCXiao Chen
Xiao Chen
KLKefan Liao
Kefan Liao
FLFengming Li
Fengming Li
HRHAI RAO
HAI RAO
Proteolysis-targeting chimeras (PROTACs) present a potentially effective strategy against various diseases via selective proteolysis. How to increase the efficacy of PROTACs remains challenging. Here, we explore the necessity of the linker, which has been deemed as an integral part of heterobifunctional PROTACs. Adopting single amino acid-based degradation signals, we find that the linker is not a required feature of the PROTACs. Notably, the linker-free PROTAC, Pro-BA, exhibits superior efficacy over its linker-bearing counterparts in degrading EML4-ALK and inhibiting lung cancer cell growth, as Pro-BA induces a stronger interaction between the target and the E3 ubiquitin ligase. Pro-BA is a water-soluble, orally administered degrader that significantly inhibits the tumor growth in a xenograft mouse model. The broad applicability of this linker-free PROTAC strategy is further validated through the development of BCR-ABL degrader. Our study introduces a design paradigm for PROTACs, potentially facilitating the advancement of more efficient therapeutic degraders.

15 October 2015 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GYGuiyang Yao
Guiyang Yao
ZPZhengyin Pan
Zhengyin Pan
CWChunlei Wu
Chunlei Wu
WWWei Wang
Wei Wang
LFLijing Fang
Lijing Fang
WSWu Su
Wu Su

12 January 2017 in RSC Advances
Verified
Journal Article
Open access
PDF file
CWChunlei Wu
Chunlei Wu
ZPZhengyin Pan
Zhengyin Pan
GYGuiyang Yao
Guiyang Yao
WWWei Wang
Wei Wang
LFLijing Fang
Lijing Fang
WSWu Su
Wu Su
A new series of teixobactin analogues were synthesized via an oxidative cyclative cleavage approach using aryl hydrazide resin as the solid support. Structure–activity relationship studies revealed that the guanidine or amine group at position 10, the hydroxyl group of Ser7 residue and the NH proton of the N-terminal Phe1 residue are critical to the antibacterial activities, while side chain size and functional group changes are tolerated at position 4. These findings will facilitate the development of new teixobactin analogues with enhanced pharmacological properties.

29 June 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JZJianchao Zhang
Jianchao Zhang
CMCaibing Ma
Caibing Ma
YYYongjun Yu
Yongjun Yu
CLChaowei Liu
Chaowei Liu
LFLijing Fang
Lijing Fang
HRHAI RAO
HAI RAO
Proteolysis-targeting chimera (PROTAC) that specifically targets harmful proteins for destruction by hijacking the ubiquitin-proteasome system is emerging as a potent anticancer strategy. How to efficiently modulate the target degradation remains a challenging issue. In this study, we employ a single amino acid-based PROTAC, which uses the shortest degradation signal sequence as the ligand of the N-end rule E3 ubiquitin ligases to degrade the fusion protein BCR (breakpoint cluster region)-ABL (Abelson proto-oncogene), an oncogenic kinase that drives the progression of chronic myeloid leukemia. We find that the reduction level of BCR-ABL can be easily adjusted by substituting different amino acids. Furthermore, a single PEG linker is found to achieve the best proteolytic effect. Our efforts have resulted in effective degradation of BCR-ABL protein by the N-end rule pathway and efficient growth inhibition of K562 cells expressing BCR-ABL in vitro and blunted tumor growth in a K562 xenograft tumor model in vivo. The PROTAC presented has unique advantages including lower effective concentration, smaller molecular size, and modular degradation rate. Demonstrating the efficacy of the N-end rule-based PROTACs in vitro and in vivo, our study further expands the limited degradation pathways currently available for PROTACs in vivo and is easily adapted for broader applications in targeted protein degradation.

9 January 2025 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
BCBinghua Cheng
Binghua Cheng
MLMeiqing Li
Meiqing Li
JZJiwei Zheng
Jiwei Zheng
JLJiaming Liang
Jiaming Liang
YLYanyan Li
Yanyan Li
HLHongchang Li
Hongchang Li